Schöffski P, et al. - In patients with advanced/metastatic papillary renal-cell carcinoma type 1 (PRCC1) with or without MET mutations (MET+ and MET-), this phase II trial prospectively determined the efficacy and safety of crizotinib. Researchers observed that crizotinib was active and well tolerated, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification. They also noticed sporadic, durable responses in MET- and unknown MET status cases. This suggested the presence of other alterations of MET or alternative pathways.